GLP-1 weight loss after one year: what the data actually shows

What did @paigemccabex actually say?

Honestly? Almost nothing. The transcript from this video is entirely song lyrics, not health commentary. The creator didn't make a single spoken medical claim. What we have instead is a transformation-style video captioned "Been on my lil shot for over a year!" with hashtags pointing to Wegovy and GLP-1 medications. The implicit message, a before-and-after framing with a weight loss drug, does more communicating than any words did.

This matters because implicit claims in health content are still claims. A video framed around weight loss transformation while tagging a prescription medication sends a clear signal to viewers: this drug worked for me. That's worth examining even when no one said a word about dosing, mechanisms, or outcomes. The caption alone, referencing "my lil shot" over a year-long period, implies sustained use and presumably sustained results.

Does the science back this up?

The broader implication, that semaglutide (Wegovy) supports meaningful weight loss over a year or more, is actually well-supported. This is one of the better-documented areas in recent obesity pharmacology.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that adults taking 2.4mg semaglutide weekly lost an average of 14.9% of body weight over 68 weeks compared to 2.4% in the placebo group. That's a substantial, clinically meaningful difference. A follow-up analysis by Davies et al. (2021, Diabetes Care) confirmed that weight loss effects were largely maintained with continued use, which aligns with the creator's implication of year-plus results.

The catch, and it's a real one, is that these results come from controlled trials with lifestyle intervention components. Real-world outcomes vary. Adherence drops off. Side effects lead to discontinuation in a meaningful percentage of users. A transformation video doesn't capture any of that complexity.

What did they get wrong (or right)?

Credit where it's due: tagging the correct brand name (Wegovy, not Ozempic) shows awareness that these are distinct products with different approved indications, even if the video doesn't explain that. Many creators conflate the two, so the accurate hashtag use is a small but real distinction.

What's missing is everything else. There's no mention of side effects, which for semaglutide include nausea, vomiting, and gastrointestinal issues significant enough that roughly 4-7% of trial participants discontinued use (Wilding et al., 2021). There's no acknowledgment that weight often returns after stopping the medication. A 2022 study in Diabetes, Obesity and Metabolism (Rubino et al.) found participants regained about two-thirds of lost weight within a year of discontinuing semaglutide.

The video also can't tell you whether this person's results are typical, atypical, or somewhere in between. Transformation content is survivorship bias in action. You see the people it worked for. The algorithm doesn't surface the people who stopped at week six because of nausea.

What should you actually know?

Wegovy (semaglutide 2.4mg) is an FDA-approved medication for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It is a prescription drug and requires medical supervision. It is not the same product as Ozempic, which is approved for type 2 diabetes management, even though both contain semaglutide.

Long-term use appears to be where these medications show sustained benefit. Stopping the drug typically reverses much of the weight loss, which means this is closer to a chronic treatment than a short-term intervention. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) also found cardiovascular benefits in high-risk patients, suggesting the drug's utility may extend beyond weight loss alone.

What a one-year transformation TikTok cannot tell you: whether you're a candidate for this medication, what the side effect profile looks like for you personally, or what happens to the results if insurance coverage changes or supply issues arise, both of which have been documented problems with GLP-1 medications in recent years.